A Study of LY2228820 for Recurrent Ovarian Cancer
by on Monday, August 13th, 2012 | No Comments
Condition: Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Interventions: Drug: LY2228820; Drug: Carboplatin; Drug: Placebo; Drug: Gemcitabine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting – verified August 2012
See the original post here: A Study of LY2228820 for Recurrent Ovarian Cancer